Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
- The Company's Interim Chief Executive Officer, Thomas Jensen, stated, “2023 was a year of remarkable achievements for Allarity Therapeutics as we made significant strides in advancing our DRP®-guided drug development.
- Announced leadership changes and strategic advisory engagement:
Appointment of co-founder Thomas H. Jensen as Interim Chief Executive Officer in December 2023. - With nearly two decades at Allarity Therapeutics, Jensen brings extensive experience and a deep understanding of the company’s DRP® to his new role.
- Net Loss from Operations: Net Loss from Operations was $17.1 million for 2023, compared to $34 million for 2022.